Purpose: To investigate efficacy and patency status of stent graft implantation in the treatment of hepatic artery pseudoaneurysm.
Materials And Methods: A retrospective analysis of patients who had undergone endovascular treatment of hepatic artery pseudoaneurysms between 2011 and 2020 was performed. Medical records were examined to obtain patients' surgical histories and to screen for active bleeding. Angiographic data on vascular access, target vessel, material used and technical success, defined as the exclusion of the pseudoaneurysm by means of a stent graft with sufficient control of bleeding, were collected. Vessel patency at follow-up CT was analyzed and classified as short-term (< 6 weeks), mid-term (between 6 weeks and 1 year), and long-term patency (> 1 year). In case of stent occlusion, collateralization and signs of hepatic hypoperfusion were examined.
Results: In total, 30 patients were included and of these, 25 and 5 had undergone stent graft implantation and coiling, respectively. In patients with implanted stent grafts, technical success was achieved in 23/25 patients (92%). Follow-up CT scans were available in 16 patients, showing stent graft patency in 9/16 patients (56%). Short-term, mid-term, and long-term short-term stent patency was found in 81% (13/16), 40% (4/10), and 50% (2/4). In patients with stent graft occlusion, 86% (6/7) exhibited maintenance of arterial liver perfusion via collaterals and 14% (1/7) exhibited liver abscess during follow-up.
Conclusion: Stent graft provides an effective treatment for hepatic artery pseudoaneurysms. Even though patency rates decreased as a function of time, stent occlusion was mainly asymptomatic due to sufficient collateralization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716354 | PMC |
http://dx.doi.org/10.1007/s00270-021-02993-0 | DOI Listing |
BMJ Open Gastroenterol
January 2025
Department of Gastroenterology, Hepatology and Transplant Medicine, University of Duisburg-Essen, Essen, Germany
Objective: Secondary sclerosing cholangitis (SSC) represents a disease with a poor prognosis increasingly diagnosed in clinical settings. Notably, SSC in critically ill patients (SSC-CIP) is the most frequent cause. Variables associated with worse prognosis remain unclear.
View Article and Find Full Text PDFAm J Transplant
January 2025
Erasmus MC Transplant Institute, Division of HPB/Transplant Surgery, Erasmus Medical Centre Rotterdam. Electronic address:
With an increasingly aging population, both end-stage renal disease and peripheral artery disease become more prevalent. Peripheral artery disease is increasingly treated with endovascular procedures. Endovascular stenting of the external iliac artery (EIA) is often considered a contraindication for kidney transplantation, as clamping of the artery could result in possible injuring of the stent.
View Article and Find Full Text PDFJ Cardiothorac Vasc Anesth
December 2024
Penn State Milton S. Hershey Medical Center, Hershey, PA.
J Int Med Res
January 2025
Department of Surgery, Chonnam National University Hospital, Gwangju, Republic of Korea.
The popliteal artery segment is particularly challenging for endovascular treatment. Stents used for treating popliteal artery lesions are usually associated with an increased risk of stent fracture and re-occlusion. The Supera stent is designed to withstand mechanical stress, with a low risk of fracture.
View Article and Find Full Text PDFIntroduction: The management of urinary tract stones, particularly kidney allograft stones, presents unique challenges for kidney transplant recipients because of their prevalence and specific clinical considerations. Here, we describe a case in which percutaneous nephrolithotomy was successfully used to fragment a large kidney allograft stone ≥20 mm in size.
Case Presentation: A 57-year-old woman who underwent ureteroureterostomy post simultaneous pancreas-kidney transplantation presented with gross hematuria after 15 years.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!